{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=200+mg+Microcrystalline+Cellulose", "query": { "intervention": "200 mg Microcrystalline Cellulose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=200+mg+Microcrystalline+Cellulose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T11:34:19.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04640168", "title": "Adaptive COVID-19 Treatment Trial 4 (ACTT-4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1010, "start_date": "2020-12-02", "completion_date": "2021-06-18", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640168" }, { "nct_id": "NCT02717988", "title": "Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SKI-O-703 capsule", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oscotec Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2015-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717988" }, { "nct_id": "NCT07830056", "title": "Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived Personnel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sleep Deprivation", "Cold Exposure" ], "interventions": [ { "name": "Modafinil (M)", "type": "DRUG" }, { "name": "200 mg Microcrystalline Cellulose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United States Army Research Institute of Environmental Medicine", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "17 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "17 Years to 39 Years" }, "enrollment_count": 33, "start_date": "2025-02-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 1, "location_summary": "Natick, Massachusetts", "locations": [ { "city": "Natick", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07830056" }, { "nct_id": "NCT06516887", "title": "Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Lung Adenocarcinoma" ], "interventions": [ { "name": "bemcentinib", "type": "DRUG" }, { "name": "pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-12-27", "completion_date": "2026-05-21", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06516887" }, { "nct_id": "NCT03165734", "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Physician's Choice medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Orphan Biovitrum", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2017-06-26", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03165734" }, { "nct_id": "NCT03388762", "title": "RCT of a Polyherbal Dietary Supplement for Prediabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prediabetic State" ], "interventions": [ { "name": "GlucoSupreme™ Herbal", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-12-05", "completion_date": "2020-01-01", "has_results": false, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Cincinnati, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03388762" }, { "nct_id": "NCT03667690", "title": "Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia", "Mycoses", "Fungal Infection", "Invasive Candidiases" ], "interventions": [ { "name": "Rezafungin for Injection", "type": "DRUG" }, { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" }, { "name": "oral placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2018-10-07", "completion_date": "2021-10-07", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03667690" }, { "nct_id": "NCT00780325", "title": "Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CG100649 (2 mg)", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "CG100649 (8 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 26, "start_date": "2008-10", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00780325" }, { "nct_id": "NCT04401579", "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1033, "start_date": "2020-05-08", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401579" }, { "nct_id": "NCT00593463", "title": "Drug Discrimination in Methadone-Maintained Humans Study 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Dependence" ], "interventions": [ { "name": "Cycloserine", "type": "DRUG" }, { "name": "Diltiazem", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Isradipine", "type": "DRUG" }, { "name": "Naloxone", "type": "DRUG" }, { "name": "Nifedipine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Saline", "type": "DEVICE" }, { "name": "Verapamil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2006-09", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2011-03-11", "last_synced_at": "2026-09-24T11:34:19.134Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593463" } ] }